Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Inflammatory osteolysis: a conspiracy against bone
Gabriel Mbalaviele, … , Georg Schett, Steven L. Teitelbaum
Gabriel Mbalaviele, … , Georg Schett, Steven L. Teitelbaum
Published June 1, 2017
Citation Information: J Clin Invest. 2017;127(6):2030-2039. https://doi.org/10.1172/JCI93356.
View: Text | PDF
Review

Inflammatory osteolysis: a conspiracy against bone

  • Text
  • PDF
Abstract

There are many causes of inflammatory osteolysis, but regardless of etiology and cellular contexts, the osteoclast is the bone-degrading cell. Thus, the impact of inflammatory cytokines on osteoclast formation and function was among the most important discoveries advancing the treatment of focal osteolysis, leading to development of therapeutic agents that either directly block the bone-resorptive cell or do so indirectly via cytokine arrest. Despite these advances, a substantial number of patients with inflammatory arthritis remain resistant to current therapies, and even effective anti-inflammatory drugs frequently do not repair damaged bone. Thus, insights into events such as those impacted by inflammasomes, which signal through cytokine-dependent and -independent mechanisms, are needed to optimize treatment of inflammatory osteolysis.

Authors

Gabriel Mbalaviele, Deborah V. Novack, Georg Schett, Steven L. Teitelbaum

×

Figure 2

The inflammasomes in osteolysis.

Options: View larger image (or click on image) Download as PowerPoint
The inflammasomes in osteolysis.
Cytokines such as TNF induce the expres...
Cytokines such as TNF induce the expression of pro–IL-1β, which lacks the signal peptide for secretion. Recognition of damage- or pathogen-associated molecular patterns (DAMPs or PAMPs) by the receptor/sensor component of the inflammasome (e.g., NLRP3, NLRC4), or activating mutations of some of these receptors, leads to the assembly of the inflammasome, a protein complex containing the receptor, apoptosis-associated speck-like protein containing a CARD (ASC) and caspase 1. Once assembled, this active complex cleaves pro–IL-1β into active IL-1β and triggers cascades that lead to PARP1 cleavage into p89 and p24 fragments. In precursors sensing DAMPs or PAMPs, cleaved PARP1 and autocrine effects of IL-1β, acting through IL-1R, promote maturation of osteoclasts into bone-resorbing cells. Secreted IL-1β can also act in a paracrine manner to increase bone resorption by nearby osteoclasts. Dashed arrows indicate multiple steps.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts